ONKURE THERAPEUTICS INC CLASS A (OKUR)
Health Care · Precision oncology / kinase inhibitors · NASDAQ
OnKure Therapeutics is a clinical-stage biotech developing precision small molecule drugs that selectively target mutated proteins to treat cancer and vascular anomalies while sparing healthy tissue.
What ONKURE THERAPEUTICS INC CLASS A does
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting specific mutations in cancer-driver proteins, particularly PI3Kα mutations in breast cancer and vascular anomalies. The company uses structure-based drug design, X-ray crystallography, and computational chemistry to create selective inhibitors that target oncogenic mutant forms of proteins while sparing the wild-type version, aiming to improve efficacy and reduce toxicity. The company's lead candidate OKI-219 is in Phase 1 clinical trials (PIKture-01) for HR+ and HER2+ advanced breast cancer, with next-generation PI3Kα pan-mutant programs (OKI-345 and OKI-355) in preclinical development.
Themes: Mutation-selective cancer therapeutics, PI3K pathway inhibition, Precision oncology / breast cancer, Vascular anomalies, Kinase inhibitors
Fundamentals
- Price$3.94 as of 2026-08-21 close
- Market cap$160M as of 2026-08-21
- 1-year return+45.4% 2025-08-21 close $2.71 → 2026-08-21 close $3.94
- P/En/a earnings data not available
- ROE-49.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Beta0.10 as of 2026-08-24
- Last reported earnings2026-08-04 SEC EDGAR Form 8-K (Item 2.02)
How OKUR compares in its sector
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ONKURE THERAPEUTICS INC CLASS A looks technically
ONKURE THERAPEUTICS INC CLASS A (OKUR) is trading 9.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 167 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It made a new 20-day low about 16 trading days ago. It is 26.8% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move. Trading volume is unusually light — only about 47% of its 30-day average.
Trend
8
| Distance from the 200-day | it is trading 9.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +9.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $4.20 | $4.20 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $3.58 | $3.58 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 17 calendar days ago — the swings before that are what the structure reading is measured on | 17 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 4.49. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 167 trading days ago — a "golden cross", a bullish long-term signal | 167 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 13, below the 25 that marks a real trend) | 12.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 44, neither overbought (above 70) nor oversold (below 30) | 44.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the lower half of its 14-day range ($3.78 to $4.49) — its "stochastic" reading is 23 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 22.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $5.38 | $5.38 |
|---|---|---|
| From the 52-week high | it is 26.8% below its 52-week high (its highest price of the past year) | -26.8% |
| Above the 52-week low | it is 106.3% above its 52-week low (its lowest price of the past year) | +106.3% |
| Below the 52-week high | it is 26.8% below its highest point of the past year | 26.8% |
| Since a 20-day breakout | it made a new 20-day low about 16 trading days ago | 16 sessions |
| Since a 55-day breakout | it is trading within its recent 55-day range, with no fresh breakout up or down | 0 sessions |
| All-time high | its highest closing price on record is $171.80 (set on 2021-04-09) | $171.80 |
| Given back of the 52-week move | over the past year its closes ranged ($2.00 to $5.27), and it has given back roughly a third of its rise from last year’s low — 41% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $3.14 to $3.25. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 40.7% |
| From the all-time high | it is 97.7% below its all-time high | -97.7% |
| Nearest price level | it is trading 0.8% below a resistance level at $3.97 — a price it turned at twice since 2026-04-10, most recently on 2026-06-24. Since 2024-08-21 it has 5 such levels below the current price and 6 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +0.8% |
| All-time low | its lowest closing price on record is $1.70 (set on 2025-05-13) | $1.70 |
| Above the all-time low | it is 131.8% above its all-time low | +131.8% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 1% of the past ~6 months), which often precedes a bigger move | 1st percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.2959 between its high and its low — about 7.5% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.2959 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $3.83 and $4.23 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $3.83 – $4.03 – $4.23 |
| Typical daily range (% of price) | its price moves about 7.5% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.5% |
| Stretch from the 200-day average | it is trading 1.2 daily ranges above its 200-day average price (9.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.2 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is unusually light — only about 47% of its 30-day average | 0.47× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 20.5% since the prior reading | -20.5% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
4
| Since a doji | today it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | today |
|---|---|---|
| Since a hammer | 8 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 8 sessions ago |
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
| Since a bearish engulfing | 2 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 2 sessions ago |
Price gaps
2
| Gap at the open | it opened on 2026-08-21 0.5% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.5% |
|---|---|---|
| Gap filled | a 2.2% gap up opened on 2026-08-07 has been "filled" 10 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 10 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 7.8 percentage points (the stock lost 5.5% while the market gained 2.3%) | -7.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 6.3 percentage points (the stock lost 3.2% while the market gained 3.1%) | -6.3% |
| vs market, 6 months | over the past 6 months this stock beat the market by 40.5 percentage points (the stock gained 51.5% while the market gained 11.1%) | +40.5% |
| vs market, 12 months | over the past 12 months this stock beat the market by 24.9 percentage points (the stock gained 45.4% while the market gained 20.5%) | +24.9% |
Signal agreement
2
| Bullish technical signals | 3 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 3 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 4.8% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 6.1% of the share price. | -4.8% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 2% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $4.01 — a volume-weighted average of daily closes over 150 sessions, not a true tick-by-tick VWAP. | -1.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 3% below the average price paid since it last reported on 2026-08-04 (its 10-Q), so the typical buyer over that stretch is under water. That average is $4.07 — a volume-weighted average of daily closes over 14 sessions, not a true tick-by-tick VWAP. | -3.3% |
Price levels it has turned at before
OKUR last closed at $3.94 on 2026-08-21. Since 2024-08-21 it has turned at 5 prices below its last close and 6 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $3.97 | Resistance | 0.8% above the last close | turned there twice · 2026-04-10 to 2026-06-24 |
| $3.60 | Support | 8.6% below the last close | turned there twice · 2025-10-28 to 2026-03-30 |
| $4.47 | Resistance | 13.4% above the last close | turned there twice · 2025-03-14 to 2026-08-04 |
| $4.59 | Resistance | 16.4% above the last close | turned there three times · 2025-01-28 to 2026-06-09 |
| $3.25 | Support | 17.6% below the last close | turned there three times · 2025-10-13 to 2026-01-27 |
| $2.90 | Support | 26.5% below the last close | turned there twice · 2025-08-18 to 2026-05-19 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $4.49.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $2.76 and $3.42 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $4.49.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Pulled back from the 12-month high · MACD just crossed bearish (12/26/9) · in a Bollinger Band volatility squeeze · trendless / choppy (low ADX) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low · bollinger bands · volume and relative volume
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.33 mean, 1=Strong Buy…5=Strong Sell) — 4 analysts
- Mean price target$15.50 range $11.00 – $21.00; median $15.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for OKUR
- Consensus EPS estimate-$0.41 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Company is clinical-stage with no approved products or product revenue; development may fail or face regulatory delays, and capital requirements are substantial","PI3Kα-targeted therapies face competition from existing PI3K inhibitors and other cancer treatments; clinical development requires continued enrollment and positive efficacy data","Macroeconomic, geopolitical, and regulatory developments including inflation, credit market tightening, and policy changes could adversely affect supply chain, manufacturing, regulatory compliance costs, and approval timelines"]
What changed in the latest 10-Q
AI-assisted comparison of OKUR's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing adds reference to audited consolidated financial statements for years ended December 31, 2025 and 2024 in the Annual Report on Form 10-K for the year ended December 31, 2025 (filed 2026-05-05)
- Newer filing adds section on 'Next-Generation PI3K α Pan-Mutant Programs' describing OKI-345 and OKI-355 candidates (filed 2026-05-05)
- Newer filing adds that company plans to submit IND applications for OKI-345 and OKI-355 in first half of 2027 (filed 2026-05-05)
- Newer filing adds 'PIKture-01 Trial and OKI-219 Update' section with enrollment data (n=38 single-agent, n=33 combination) and statement that company does not plan to pursue further clinical development of OKI-219 independently (filed 2026-05-05)
- Newer filing reports accumulated deficit of $229.4 million as of March 31, 2026 (filed 2026-05-05)
- Newer filing reports net losses of $15.2 million for three months ended March 31, 2026 and $59.5 million for year ended December 31, 2025 (filed 2026-05-05)
- Newer filing reports cash and cash equivalents of $192.1 million as of March 31, 2026 (filed 2026-05-05)
- Removed:
- Older filing included 'Forward-Looking Statements' section with risk disclaimers and definition of forward-looking statement terminology (filed 2025-11-06)
- Older filing contained detailed description of Merger mechanics including reverse stock split, name change, and reclassification of common stock (filed 2025-11-06)
- Older filing described Concurrent Financing with 2,839,005 shares at $22.895 per share for $65.0 million (filed 2025-11-06)
- Older filing stated registration statement was filed in October 2024 (filed 2025-11-06)
- Older filing noted Common Stock began trading on Nasdaq under symbol 'OKUR' as of October 7, 2024 (filed 2025-11-06)
- Older filing described OKI-219 as lead product candidate, highly selective inhibitor of PI3K α H1047R (filed 2025-11-06)
- Older filing stated initial focus on advanced breast cancer patients with genetic subtypes (HR+ HER2- and HER2+) (filed 2025-11-06)
- Older filing noted potential expansion of OKI-219 to earlier treatment lines, other breast cancer subtypes, and other solid tumors (filed 2025-11-06)
- Older filing stated OKI-219 is in first-in-human Phase 1a/1b clinical trial (filed 2025-11-06)
- Reworded:
- Overview changed from 'cancers underserved by available therapies' to 'vascular anomalies and cancers that are underserved by available therapies' (filed 2026-05-05)
- Overview changed from 'robust pipeline of small molecule drugs' to 'pipeline of small molecule drugs' (filed 2026-05-05)
- Reference to predecessor company changed: older filing referenced 'Legacy OnKure's audited financial statements' for years ended December 31, 2024 and 2023; newer filing references 'our audited consolidated financial statements and notes thereto' for years ended December 31, 2025 and 2024 (filed 2026-05-05)
- Merger description condensed: older filing provided detailed mechanics; newer filing provides minimal statement with cross-reference to Note 1 (filed 2026-05-05)
- Notes:
- Older filing text appears truncated at end of 'Financial Overview' section
- Comparison reflects different fiscal periods: older filing for quarter ended September 30, 2025; newer filing for quarter ended March 31, 2026
Risk Factors
- Added:
- Newer filing (2026-05-05) adds bullet point: 'We will need substantial additional funding before we can complete the development of our product candidates. If we are unable to obtain such additional capital on favorable terms, on a timely basis, or at all, we would be forced to delay, reduce or eliminate our product development and clinical programs and may not have the capital required to otherwise operate our business.' (moved from later in older summary to earlier position)
- Newer filing (2026-05-05) adds bullet point: 'If we are unable to advance OKI-345 and OKI-355 through preclinical and clinical development, obtain regulatory approval and ultimately commercialize one or more of such product candidates, or experience significant delays in doing so, our business will be materially harmed.'
- Newer filing (2026-05-05) adds specific financial data: 'Our net losses were $15.2 million and $59.5 million for three months ended March 31, 2026 and the year ended December 31, 2025, respectively.'
- Removed:
- Older filing (2025-11-06) had bullet point: 'We are substantially dependent on OKI-219. If we are unable to advance OKI-219 through clinical development, obtain regulatory approval and ultimately commercialize such product candidate, or experience significant delays in doing so, our business will be materially harmed.' (removed in newer filing)
- Older filing (2025-11-06) had bullet point: 'We have limited resources and are currently focusing our efforts on OKI-219 for development in particular indications and advancing our other discovery research programs. As a result, we may fail to capitalize on programs, product candidates or indications that may be more profitable or for which there is a greater likelihood of success.' (replaced with more generic version in newer filing)
- Older filing (2025-11-06) had bullet point: 'A robust trading market for our Class A Common Stock may not develop, and the holders of our Class A Common Stock may not be able to resell their shares of our Class A Common Stock for a profit, if at all.' (removed in newer filing)
- Reworded:
- Older filing language 'our products and product candidates we may develop' changed to 'our product candidates' in newer filing (2026-05-05) in intellectual property risk factor
- Older filing had more specific reference to 'OKI-219 for development in particular indications' while newer filing uses generic language 'programs, product candidates or indications' without product name specificity
- Notes:
- The newer filing text appears truncated at 'As of March 31,' so the complete financial discussion cannot be compared
- Bullet point ordering and positioning changed between filings, making some items appear as additions/removals when they may have been repositioned
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 2 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 2 sells ($1710) — 2 selling insiders
- Last 180 days0 buys · 2 sells ($1710) — 2 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-22. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about OKUR's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding OKUR as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 477,886
- Reported value $1,978,448
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 1 increased, 2 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
OKUR had 1,187,063 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
OKUR had 2.93% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 10.57 days to cover at the same settlement.
- Reported short interest (shares) 1,187,063
- Short interest (% of shares outstanding) 2.93%
- Prior settlement (shares) 1,181,591
- Reported change 0.46%
- Days to cover (reported) 10.57
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Arcus Biosciences
- Array BioPharma (ARRY)
- Principia Biopharma / Sesen Bio
- Ideaya Biosciences (IDYA)
- GlaxoSmithKline (GSK)
- Roche/Genentech
- Novartis (NVS)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare OKUR vs…
Frequently asked questions
What does ONKURE THERAPEUTICS INC CLASS A (OKUR) do?
OnKure Therapeutics is a clinical-stage biopharmaceutical company developing precision small-molecule drugs targeting specific mutations in cancer-driver proteins, particularly PI3Kα mutations in breast cancer and vascular anomalies. The company uses structure-based drug design, X-ray crystallography, and computational chemistry to create selective inhibitors that target oncogenic mutant forms of proteins while sparing the wild-type version, aiming to improve efficacy and reduce toxicity.
What sector is ONKURE THERAPEUTICS INC CLASS A (OKUR) in?
ONKURE THERAPEUTICS INC CLASS A (OKUR) is classified in the Health Care sector. Its industry is Precision oncology / kinase inhibitors. It trades on NASDAQ.
Who are ONKURE THERAPEUTICS INC CLASS A's (OKUR) competitors?
Notable peers of ONKURE THERAPEUTICS INC CLASS A (OKUR) include Arcus Biosciences, Array BioPharma, Principia Biopharma / Sesen Bio, Ideaya Biosciences and GlaxoSmithKline. This peer set is informational only — not financial advice.
Is ONKURE THERAPEUTICS INC CLASS A (OKUR) overbought or oversold right now?
ONKURE THERAPEUTICS INC CLASS A (OKUR) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 44, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on OKUR come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.